Menu
mRNA technologies and development.
We have experience building mRNAs for a wide range of applications, including antigens, enzymes, peptides, antibodies, gene-, and cell-therapies.
We provide end-to-end research services for pre-clinical development of your mRNAs, including;
mRNA vaccines offer a promising approach to treat cancer.
Dr Seth Cheetham is supported by the Medical Research Future Fund to help develop mRNA cancer vaccines.
This support will help establish the expertise and equipment to design, manufacture and test mRNA cancer vaccines at BASE, UQ.
Australian researchers have access to these capabilities, and should contact our team if developing an mRNA cancer vaccine.
We use nanopore sequencing to analyse our mRNA. This can measure quality features (5’cap, sequence, integrity and polyA) for each single mRNA molecule.
Dr Gunter published an initial study describing the analysis of mRNA vaccines using nanopore sequencing.
We are proud to collaborate with Oxford Nanopore Technologies to develop this method for quality control testing during mRNA manufacture.
BASE scientists have expertise in mRNA production and LNP formulation, and can help with process development and scale-up.
We are developing new, cell-free methods to produce high-quality mRNA. Watch our webinar where Dr Seth Cheetham, in partnership with Integrated DNA Technologies (IDT), shows the rapid PCR amplification of DNA templates for mRNA synthesis.